ReviewBioMed research international2013
An insight into the "-omics" based engineering of streptomycetes for secondary metabolite overproduction.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Current Knowledge on CRISPR Strategies Against Antimicrobial-Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2024Review
- Whole Genome Sequencing and Biocontrol Potential ofMicroorganisms · 2024Article
- A statistical approach to enhance the productivity of Streptomyces baarensis MH-133 for bioactive compounds.Synthetic and systems biotechnology · 2024Article
- Marine Macrolides to Tackle Antimicrobial Resistance ofMarine drugs · 2022Review
- Carbon catabolite regulation of secondary metabolite formation, an old but not well-established regulatory system.Microbial biotechnology · 2022Review
- Endophytism: A Multidimensional Approach to Plant-Prokaryotic Microbe Interaction.Frontiers in microbiology · 2022Review
- Biodiversity of Secondary Metabolites Compounds Isolated from Phylum Actinobacteria and Its Therapeutic Applications.Molecules (Basel, Switzerland) · 2021Review
- Microbial and Genetic Resources for Cobalamin (Vitamin B12) Biosynthesis: From Ecosystems to Industrial Biotechnology.International journal of molecular sciences · 2021Review
- Article
- Article
- Evaluation of Sample Preparation Methods for Inter-Laboratory Metabolomics Investigation ofMetabolites · 2020Article
- Degeneration of industrial bacteria caused by genetic instability.World journal of microbiology & biotechnology · 2020Review
- Omics for Bioprospecting and Drug Discovery from Bacteria and Microalgae.Antibiotics (Basel, Switzerland) · 2020Review
- Recent Advances in Strategies for Activation and Discovery/Characterization of Cryptic Biosynthetic Gene Clusters inMicroorganisms · 2020Review
- Streptomyces sp. VN1, a producer of diverse metabolites including non-natural furan-type anticancer compound.Scientific reports · 2020Article
- Engineering actinomycetes for biosynthesis of macrolactone polyketides.Microbial cell factories · 2019Review
- Osmanicin, a Polyketide Alkaloid Isolated fromMolecules (Basel, Switzerland) · 2019Article
- Bioactive molecules from Nocardia: diversity, bioactivities and biosynthesis.Journal of industrial microbiology & biotechnology · 2019Review
- Secretome Dynamics in a Gram-Positive Bacterial Model.Molecular & cellular proteomics : MCP · 2019Article
- Use of genome-scale models to get new insights into the marine actinomycete genus Salinispora.BMC systems biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microorganisms produce a range of chemical substances representing a vast diversity of fascinating molecular architectures not available in any other system. Among them, Streptomyces are frequently used to produce useful enzymes and a wide variety of secondary metabolites with potential biological activities. Streptomyces are preferred over other microorganisms for producing more than half of the clinically useful naturally originating pharmaceuticals. However, these compounds are usually produced in very low amounts (or not at all) under typical laboratory conditions. Despite the superiority of Streptomyces, they still lack well documented genetic information and a large number of in-depth molecular biological tools for strain improvement. Previous attempts to produce high yielding strains required selection of the genetic material through classical mutagenesis for commercial production of secondary metabolites, optimizing culture conditions, and random selection. However, a profound effect on the strategy for strain development has occurred with the recent advancement of whole-genome sequencing, systems biology, and genetic engineering. In this review, we demonstrate a few of the major issues related to the potential of "-omics" technology (genomics, transcriptomics, proteomics, and metabolomics) for improving streptomycetes as an intelligent chemical factory for enhancing the production of useful bioactive compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.